TABLE 1

Food intake and baseline characteristics of E3L mice after randomization into different groups

Time (t) = 0 after 4-week run-in period.

Group	n	BW at t = 0	Food Intake^{^a}	Statin Intake	Statin Intake^{^b}	Plasma TC at t = 0	Plasma TG at t = 0
		g	g/day	mg/day	mg/kg	mM
Chow control	12	20.8 ± 0.61	3.72 ± 0.14	—	—	2.83 ± 0.21	2.83 ± 0.48
HFC-control	8	20.3 ± 1.11	2.70 ± 0.20	—	—	15.1 ± 3.49	2.41 ± 0.77
HFC-0.003% Atorvastatin	8	20.9 ± 0.82	2.61 ± 0.21	0.08	3.76	15.1 ± 1.89	2.49 ± 0.90
HFC-0.008% atorvastatin	8	21.8 ± 1.39	2.65 ± 0.13	0.21	10.1	15.1 ± 3.52	2.52 ± 0.41
HFC-0.03% pravastatin	8	20.9 ± 1.57	2.58 ± 0.18	0.77	37.2	14.9 ± 2.35	2.28 ± 0.58
HFC-0.04% pravastatin	8	21.0 ± 1.76	2.55 ± 0.18	1.02	48.7	15.2 ± 2.81	2.45 ± 0.58
HFC-0.05% lovastatin	8	20.6 ± 1.21	2.51 ± 0.11^*	1.26	60.9	15.0 ± 2.21	2.37 ± 0.40
HFC-0.07% lovastatin	8	20.9 ± 1.11	2.53 ± 0.28	1.77	84.7	14.8 ± 3.03	2.37 ± 0.50
HFC-0.03% simvastatin	8	20.7 ± 1.03	2.60 ± 0.13	0.78	37.7	15.1 ± 2.01	2.41 ± 0.38
HFC-0.06% simvastatin	8	21.5 ± 0.85	2.60 ± 0.19	1.56	72.7	14.9 ± 2.71	2.72 ± 0.34
HFC-0.0025% rosuvastatin	8	21.5 ± 0.77	2.59 ± 0.09	0.06	3.01	15.0 ± 2.50	2.57 ± 0.49
HFC-0.005% rosuvastatin	8	21.0 ± 0.89	2.55 ± 0.25	0.13	6.08	15.2 ± 2.84	2.71 ± 0.63

—, not done; BW, body weight; HFC, high-fat cholesterol diet.
↵^a Average over the 6-week treatment period.
↵^b Based on body weight at t = 0.
↵* P < 0.01 compared with HFC-control group; data are presented as mean or mean ± S.D.